Skip to main content
SpringerLink
Log in

Production of Antibodies in Hybridoma and Non-hybridoma Cell Lines

  • Chapter
  • First Online:
Animal Cell Culture

Part of the book series: Cell Engineering ((CEEN,volume 9))

Abstract

Antibody based drugs have not only advanced the prevention and treatment of a number of life threatening diseases including cancer and arthritis, but have also provided the thrust for the continued success of the biopharmaceutical and pharmaceutical industry. Currently at least seven therapeutic antibodies are listed among the top ten revenue generating pharmaceutical products. These antibodies are generally monoclonal in origin and include, chimerised, humanised and human antibody types. Recently, new classes of antibody drugs are emerging and are expected to be among the next generation of block buster drugs within the Industry. These new classes include antibody conjugates, bispecific antibodies and antibody fragments. In this chapter, we will discuss the methods used for the production of antibodies in both hybridoma and non-hybridoma cells lines. The chapter will also focus on the successful use of these antibodies as therapeutics in cancer and rheumatoid arthritis.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Aggarwal S (2014) What’s fueling the biotech engine – 2012 to 2013. Nat Biotechnol 32:32–39

    Article  CAS  PubMed  Google Scholar 

  • Ahmad A, Hart IR (1997) Mechanism of metastasis. Crit Rev Oncol/Hematol 26:163–173

    Article  CAS  Google Scholar 

  • Baguley BC (2010) Multiple drug resistance mechanisms in cancer. Mol Biotechnol 46:308–316

    Article  CAS  PubMed  Google Scholar 

  • Barbas CF 3rd, Kang AS, Lerner RA, Benkovic SJ (1991) Assembly of combinatorial antibody libraries on phage surfaces: the gene III site. Proc Natl Acad Sci U S A 88:7978–7982

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Barbas CF 3rd, Bain JD, Hoekstra DM, Lerner RA (1992) Semisynthetic combinatorial antibody libraries: a chemical solution to the diversity problem. Proc Natl Acad Sci U S A 89:4457–4461

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Bartelds GM, Krieckaert CL, Nurmohamed MT, van Schouwenburg PA et al (2011) Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 305:1460–1488

    Article  CAS  PubMed  Google Scholar 

  • Behring EA, Kitasato S (1890) Ueber das Zustandekommen der Diphtherie-Immunitaet und der Tetanus-Immunitaet bei Thieren. Deutsch Med Wochenschr 49:1113–1114

    Google Scholar 

  • Berek C, Milstein C (1987) Mutation drift and repertoire shift in the maturation of the immune response. Immunol Rev 96:23–41

    Article  CAS  PubMed  Google Scholar 

  • Birch JR, Racher AJ (2006) Antibody production. Adv Drug Deliv Rev 58:671–685

    Article  CAS  PubMed  Google Scholar 

  • Blom M, Kievit W, Fransen J, Kuper IH et al (2009) The reason for discontinuation of the first tumor necrosis factor (TNF) blocking agent does not influence the effect of a second TNF blocking agent in patients with rheumatoid arthritis. J Rheumatol 36:2171–2177

    Article  CAS  PubMed  Google Scholar 

  • Boulianne GL, Hozumi N, Shulman MJ (1984) Production of functional chimaeric mouse/human antibody. Nature 312:643–646

    Article  CAS  PubMed  Google Scholar 

  • Brenton JD, Carey LA, Ahmed AA, Caldas C (2005) Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol 23:7350–7360

    Article  CAS  PubMed  Google Scholar 

  • Bruggemann M, Taussig MJ (1997) Production of human antibody repertoires in transgenic mice. Curr Opin Biotechnol 8:455–458

    Article  CAS  PubMed  Google Scholar 

  • Buelow R, van Schooten W (2006) The future of antibody therapy. Ernst Schering Found Symp Proc 4:83–106

    PubMed  Google Scholar 

  • Buzder AM, Ibrahim NK, Francie D, Booser DJ et al (2005) Significantly higher pathologic complete remission rate after neoadjuvant therapy with Trastuzumab, paclitaxel and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2 positive breast cancer. J Clin Oncol 23:3676–3685

    Article  Google Scholar 

  • Byrne H, Conroy PJ, Whisstock JC, O’Kennedy RJ (2013) A tale of two specificities: bispecific antibodies for therapeutic and diagnostic applications. Trends Biotechnol 31:621–632

    Article  CAS  PubMed  Google Scholar 

  • Calabrese LH (2003) Molecular differences in anticytokine therapies. Clin Exp Rheumatol 21:241–248

    CAS  PubMed  Google Scholar 

  • Caramaschi P, Biasi D, Colombatti M et al (2006) Anti-TNFα therapy in rheumatoid arthritis and autoimmunity. Rheumatol Int 26:209–214

    Article  CAS  PubMed  Google Scholar 

  • Chinot OL, Wick W, Mason W (2014) Bevacizumab plus radiotherapy–temozolomide for newly diagnosed glioblastoma. N Engl J Med 370:709–722

    Article  CAS  PubMed  Google Scholar 

  • Colcher D, Pavlinkova G, Beresford G, Booth BJ et al (1998) Pharmacokinetics and biodistribution of genetically-engineered antibodies. Q J Nucl Med 42:225–241

    CAS  PubMed  Google Scholar 

  • Conroy PJ et al (2009) Antibody production, design and use for biosensor-based applications. Semin Cell Dev Biol 20:10–26

    Article  CAS  PubMed  Google Scholar 

  • Coussens L, Yang-Feng TL, Liao YC et al (1985) Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230:1132–1139

    Article  CAS  PubMed  Google Scholar 

  • Dall’Acqua WF, Damschroder MM, Zhang J, Woods RM et al (2005) Antibody humanization by framework shuffling. Methods 36:43–60

    Article  PubMed  Google Scholar 

  • De la Cruz Edmonds MC, Tellers M, Chan C, Salmon P et al (2006) Development of transfection and high-producer screening protocols for the CHOK1SV cell system. Mol Biotechnol 34:179–190

    Article  PubMed  Google Scholar 

  • De Rycke L, Van Damme N, Kruitof E et al (2003) Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondyloarthritis. Arthritis Rheum 48:1015–1023

    Article  PubMed  Google Scholar 

  • Edelman GM, Cunningham BA, Gall WE, Gottlieb PD et al (1969) The covalent structure of an entire immunoglobulin molecule. Proc Natl Acad Sci U S A 63:78–85

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • El Bakri A, Nelson PN, Abu Odeh RO (2010) The state of antibody therapy. Hum Immunol 71:1243–1250

    Article  Google Scholar 

  • Fidler IJ (2003) The pathogenesis of cancer metastasis: the seed and soil hypothesis revisited. Nat Rev Cancer 3:1–6

    Article  Google Scholar 

  • Flemming A (2014) Fine-tuning antibody–drug conjugates. Nat Rev Drug Discov 13:178. doi:10.1038/nrd4266

    Article  CAS  PubMed  Google Scholar 

  • Geho DH, Bandle RW, Clair T, Liotta LA (2005) Physiological mechanisms of tumour cell invasion and migration. Physiology 20:194–200

    Article  CAS  PubMed  Google Scholar 

  • Gilbert MR, Dignam JJ, Armstrong TS et al (2014) A randomized trial of Bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370:699–708

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Gram H, Marconi LA, Barbas CF, Collet TA et al (1992) In vitro selection and affinity maturation of antibodies from a naive combinatorial immunoglobulin library. Proc Natl Acad Sci U S A 89:3576–3580

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Green LL, Hardy MC, Maynard-Currie CE et al (1994) Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs. Nat Genet 7:13–21

    Article  CAS  PubMed  Google Scholar 

  • Hamburg MA, Collins FS (2010) The path to personalized medicine. N Engl J Med 363:301–304

    Article  CAS  PubMed  Google Scholar 

  • Hamers-Casterman C, Atarhouch T, Muyldermans S et al (1993) Naturally occurring antibodies devoid of light chains. Nature 363:446–448

    Article  CAS  PubMed  Google Scholar 

  • Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57–70

    Article  CAS  PubMed  Google Scholar 

  • Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 44:646–674

    Article  Google Scholar 

  • Herzig M, Christofori G (2002) Recent advances in cancer research: mouse models of malignant disease. Clin Cancer Res 3:2623–2629

    Google Scholar 

  • Holliger P, Hudson PJ (2005) Engineered antibody fragments and the rise of single domains. Nat Biotechnol 23:1126–1136

    Article  CAS  PubMed  Google Scholar 

  • Hynes NE, Lane HA (2005) ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5:341–354

    Article  CAS  PubMed  Google Scholar 

  • Ignatiadis M, Desmedt C, Sotiriou C et al (2009) HER-2 as a target for breast cancer therapy. Clin Cancer Res 15:1848–1852

    Article  CAS  PubMed  Google Scholar 

  • Jakobovits A, Amado RG, Yang X, Roskos L, Schwab G (2007) From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice. Nat Biotechnol 25:1134–1143

    Article  CAS  PubMed  Google Scholar 

  • Jones PT, Dear PH, Foote J, Neuberger MS, Winter G (1986) Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 321:522–525

    Article  CAS  PubMed  Google Scholar 

  • Kelley B (2007) Very large-scale monoclonal antibody purification –the case for conventional unit operations. Biotechnol Prog 23:995–1008

    CAS  PubMed  Google Scholar 

  • Khazaeli MB, Conry RM, LoBuglio AF (1994) Human immune response to monoclonal antibodies. J Immunother Emphasis Tumor Immunol 15:42–52

    Article  CAS  PubMed  Google Scholar 

  • King CR, Kraus MH, Aaronson SA (1985) Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science 229:974–976

    Article  CAS  PubMed  Google Scholar 

  • Köhler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256(5517):495–497

    Article  PubMed  Google Scholar 

  • Llewelyn MB, Hawkins RE, Russell SJ (1992) Monoclonal antibodies in medicine: discovery of antibodies. Br Med J 305:1269–1272

    Article  CAS  Google Scholar 

  • Marks JD, Hoogenboom HR, Bonnert TP, McCafferty J, Griffiths AD, Winter G (1991) By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J Mol Biol 222:581–597

    Article  CAS  PubMed  Google Scholar 

  • McCafferty J, Griffiths AD, Winter G, Chiswell DJ (1990) Phage antibodies: filamentous phage displaying antibody variable domains. Nature 348:552–554

    Article  CAS  PubMed  Google Scholar 

  • McDermott U, Downin JR, Stratton MR (2011) Genomics and the continuum of cancer care. N Engl J Med 364:340–350

    Article  CAS  PubMed  Google Scholar 

  • Mehlen P, Puisieux A (2006) Metastasis: a question of life and death. Nat Rev Cancer 6:449–458

    Article  CAS  PubMed  Google Scholar 

  • Morrison SL, Johnson MJ, Herzenberg LA, Oi VT (1984) Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci U S A 81:6851–6855

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Muyldermans S (2001) Single domain camel antibodies: current status. Rev Mol Biotechnol 74:277–302

    Article  CAS  Google Scholar 

  • Nelson PN et al (2000) Monoclonal antibodies. Mol Pathol 53:111–117

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Neuberger MS (1983) Expression and regulation of immunoglobulin heavy chain gene transfected into lymphoid cells. EMBO J 2:1373–1378

    CAS  PubMed Central  PubMed  Google Scholar 

  • Ohlin M, Zouali M (2003) The human antibody repertoire to infectious agents: implications for disease pathogenesis. Mol Immunol 40:1–11

    Article  CAS  PubMed  Google Scholar 

  • Parashar A et al (2011) Bispecific antibodies for diagnostic applications. In: Kontermann RE (ed) Bispecific antibodies, 1st edn. Springer, Berlin/Heidelberg, pp 349–367

    Chapter  Google Scholar 

  • Pascual V, Capra JD (1991) Human immunoglobulin heavy chain variable genes: organisation, polymorphism and expression. Adv Immunol 49:1–74

    Article  CAS  PubMed  Google Scholar 

  • Perou CM, Sorlie T, Eisen MB et al (2000) Molecular portraits of human breast tumours. Nature 406:747–752

    Article  CAS  PubMed  Google Scholar 

  • Pescovitz MD (2006) Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action. Am J Transplant 6:859–866

    Article  CAS  PubMed  Google Scholar 

  • Pillay V, Gan HK, Scott AM (2011) Antibodies in oncology. New Biotechnol 28:518–529

    Article  CAS  Google Scholar 

  • Polyak K (2001) On the birth of breast cancer. Biochim Biophys Acta 1552:1–13

    CAS  PubMed  Google Scholar 

  • Rakha EA, El-Sayed ME, Green AR et al (2007) Prognostic markers in triple-negative breast cancer. Cancer 109:25–32

    Article  CAS  PubMed  Google Scholar 

  • Reichert J, Valge-Archer V (2007) Development trends for monoclonal antibody cancer therapeutics. Nat Rev Drug Discov 6:349–356

    Article  CAS  PubMed  Google Scholar 

  • Riechmann L, Clark M, Waldmann H, Winter G (1988) Reshaping human antibodies for therapy. Nature 332:323–327

    Article  CAS  PubMed  Google Scholar 

  • Roguska MA, Pedersen JT, Keddy CA et al (1994) Humanization of murine monoclonal antibodies through variable domain resurfacing. Proc Natl Acad Sci U S A 91:969–973

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Rosenblum H, Amital H (2011) Anti-TNF therapy: safety aspect of taking the risk? Autoimmun Rev 10:563–568

    Article  PubMed  Google Scholar 

  • Sapra P, Shor B (2013) Monoclonal antibody-based therapies in cancer: advances and challenges. Pharmacol Ther 138:452–469

    Article  CAS  PubMed  Google Scholar 

  • Shin SU, Morrison SL (1989) Production and properties of chimeric antibody molecules. Methods Enzymol 178:459–476

    Article  CAS  PubMed  Google Scholar 

  • Shukla AA, Thommes J (2010) Recent advances in large-scale production of monoclonal antibodies and related proteins. Trends Biotechnol 28:253–261

    Article  CAS  PubMed  Google Scholar 

  • Slamon DJ, Clark GM, Wong SG, Levin WJ et al (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177–182

    Article  CAS  PubMed  Google Scholar 

  • Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783–792

    Article  CAS  PubMed  Google Scholar 

  • Smith GP (1985) Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 228:1315–1317

    Article  CAS  PubMed  Google Scholar 

  • Stasi R (2010) Rozrolimupab, symphobodies against rhesus D, for the potential prevention of hemolytic disease of the newborn and the treatment of idiopathic thrombocytopenic purpura. Curr Opin Mol Ther 12:734–740

    CAS  PubMed  Google Scholar 

  • Stokes J Jr, Maris EP, Gellis SS (1944) The use of concentrated normal human serum gamma globulin (human immune serum globulin) in the prophylaxis and treatment of measles. J Clin Invest 23:53

    Article  Google Scholar 

  • Tian F et al (2014) A general approach to site-specific antibody drug conjugates. Proc Natl Acad Sci U S A 111:1766–1771

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Tonegawa S (1983) Somatic generation of antibody diversity. Nature 302:573–581

    Article  Google Scholar 

  • Valesini G, Lannuccelli C, Marocchi E, Pascoli L, Scalzi V et al (2007) Biological and clinical effects of anti-TNFα treatment. Autoimmun Rev 7:35–41

    Article  CAS  PubMed  Google Scholar 

  • Van’t Veer LJ, Weigelt B (2003) Road map to metastasis. Nat Med 9:999–1000

    Article  Google Scholar 

  • Walsh G (2010) Biopharmaceutical benchmarks 2010. Nat Biotechnol 28:917–926

    Article  CAS  PubMed  Google Scholar 

  • Walsh, G (2013) Milestones and moderate progress in 2012 drug approvals. Biopharm Int 26:54–56

    Google Scholar 

  • Weigelt B, Peterse JL, Van’t Veer L (2005) Breast cancer metastasis: markers and models. Nat Rev Cancer 5:591–602

    Article  CAS  PubMed  Google Scholar 

  • Weiner LM et al (2010) Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol 10:317

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Wolff AC, Hammond ME, Schwartz JN et al (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118–145

    Article  CAS  PubMed  Google Scholar 

  • Wurm FM (2004) Production of recombinant protein therapeutics in cultivated mammalian cells. Nat Biotechnol 22:1393–1398

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. UCD School of Chemical & Bioprocess Engineering, University College Dublin, Belfield, Dublin, Ireland

    Susan McDonnell

Authors
  1. Susan McDonnell
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Susan McDonnell .

Editor information

Editors and Affiliations

  1. University College Dublin, Dublin, Ireland

    Mohamed Al-Rubeai

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

McDonnell, S. (2015). Production of Antibodies in Hybridoma and Non-hybridoma Cell Lines. In: Al-Rubeai, M. (eds) Animal Cell Culture. Cell Engineering, vol 9. Springer, Cham. https://doi.org/10.1007/978-3-319-10320-4_3

Download citation

Publish with us

Policies and ethics

Search

Navigation